The case for AI-driven cancer clinical trials - The efficacy arm in silico.

Autor: Kolla L; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Gruber FK; GNS Healthcare, Somerville, MA, USA., Khalid O; GNS Healthcare, Somerville, MA, USA., Hill C; GNS Healthcare, Somerville, MA, USA. Electronic address: colin@gnshealthcare.com., Parikh RB; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jazyk: angličtina
Zdroj: Biochimica et biophysica acta. Reviews on cancer [Biochim Biophys Acta Rev Cancer] 2021 Aug; Vol. 1876 (1), pp. 188572. Date of Electronic Publication: 2021 May 31.
DOI: 10.1016/j.bbcan.2021.188572
Abstrakt: Pharmaceutical agents in oncology currently have high attrition rates from early to late phase clinical trials. Recent advances in computational methods, notably causal artificial intelligence, and availability of rich clinico-genomic databases have made it possible to simulate the efficacy of cancer drug protocols in diverse patient populations, which could inform and improve clinical trial design. Here, we review the current and potential use of in silico trials and causal AI to increase the efficacy and safety of traditional clinical trials. We conclude that in silico trials using causal AI approaches can simulate control and efficacy arms, inform patient recruitment and regimen titrations, and better enable subgroup analyses critical for precision medicine.
(Copyright © 2021 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: